Key Takeaways
- Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).
- The drug, Dupixent, showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies.
- The drug was previously approved for the treatment of other conditions, including atopic dermatitis and asthma.
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).
The drug, Dupixent, is the first biologic medicine approved in the U.S. for the treatment of COPD, a respiratory disease that restricts airflow and damages the lungs. The treatment showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies, the companies reported.
COPD Approval Adds to Drug’s Applications
Dupixent was previously approved for the treatment of other conditions, including atopic dermatitis and asthma.
Shares of Regeneron ticked up 0.2% Friday, while Sanofi shares listed in the U.S. rose 1.1%. The companies’ stocks are up about 19% and 16%, respectively, since the start of the year.